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From the National Heart Hospital, London W.] The search for an ideal valve substitute continues, and we for our part have remained firmly in favour of the use of biological tissue.
There are many arguments that can be invoked to support this principle, the most clearly established being that they provide a central unimpeded flow orifice and a total freedom from thromboembolism without the use of anticoagulants. Also, red cell destruction is minimal or absent. While mechanical valves change continuously in design in an attempt to match these advantages, their deficiencies in these three areas remain.
My subsequent remarks will be confined to aortic valvar replacements and I shall consider homografts, pulmonary autografts, and autologous fascia lata. I have no experience with heterografts. My results with homograft valves are as follows: 394 valves have been inserted in the aortic area, of which 372 were isolated aortic valvar replacements, and these only will be discussed to exclude the problems related to multiple valve replacements. The follow-up extends over the eight-year period to the middle of this year.
Homograft valves
The operative and late mortality has been as follows: early i8'5 per cent, late I3'4 per cent.
Although both operative and late mortality has been falling, you will notice that there has also been a reduced utilization of these valves. This has been because ofthe observed increasing complication rate.
Complications have included early valve failure or regurgitation due to technical malseating and late failure from calcific or atrophic degeneration. Infection has not been an important complication (6%).
Of course, only cases coming to operation or necropsy can be graded with accuracy as calcific or atrophic degeneration, but of 6i known cases of late failure 20 showed calcification and 26 atrophic degeneration.
An important observation, and one with clinical implications, is that in our experience late degeneration in a homograft is never sudden but progresses slowly over a number of months. The first feature of failure is the development of a diastolic murmur and less frequently the detection of a systolic thrill, so that the appearance of late diastolic murmurs is our best clinical index of valve failure.
I am of course aware that many factors may be responsible for valve degeneration, including the method of valve preparation, and most of these degenerated valves were freezedried. However, there is no clear evidence in this group of cases that any particular method of preparation and storage is preferable, although we concede that one should avoid techniques which damage the basic cusp structure.
Nor have we supporting evidence from our experimental work in sheep in favour of a particular method of preparation or storage, since freeze-dried, frozen, irradiated, and fresh non-living homologous cusps underwent similar degeneration after implantation. All were acellular at one year and many showed dilatation or aneurysm formation when sewn in the descending aorta. Calcification was, however, rare in the fresh cusp implants.
The Autologous fascia lata valves I am aware of the increased technical difficulties of this operation and of the need to replace the excised pulmonary valve and right ventricular outflow tract. This has been achieved with an aortic homograft in 89 cases, but in the last i i cases a fascia lata tube and valve made from the patient's own living tissue has been used. This means that the operation is now completed entirely with autologous living tissue. To date no long-term complications can be attributed to the right ventricular reconstruction.
For the young patient under 40 years of age with isolated aortic valve disease, and particularly in those rare instances where aortic valve replacement is needed in children, this is my operation of election at present. It seems to meet the criteria we have defined -namely, a central unimpeded flow, an absence of emboli, and the use of autologous living tissue.
At the same time, I like others am conscious of the need for a more easily inserted valve, one that is predictably competent and readily available in varying sizes but embodying all the features mentioned so far.
Here we have hopes that fascia lata valves constructed at operation will supply an answer, and in this we are encouraged by our own results and the long-term results of Senning.
These frame-mounted fascia lata valves represent a compromise between the rigid mechanical prosthesis and the homograft or autograft, and, as inevitably happens with compromises, we inherit some of the advantages and disadvantages of both. These have included gradients, haemolysis, and an increased incidence of infection.
Gradients and haemolysis we believe we have eliminated with improved structural design, and the incidence of infection is a Aortic valvar replacements 41 feature we hope to be able to control. It is, however, at present significantly above that for both homografts and autografts.
We do know, however, from a study of these valves over a period of over a year that they can remain as fully functional living structures. Also, judging by Senning's reported results, they do not appear to become rigid or calcify for periods up to seven years. However, we are still somewhat concerned about the need for a rigid frame in order to achieve competence and believe it runs counter to the original biological valve concept.
More If we are to continue to use homografts we must develop methods of storage which will preserve the structural integrity and if possible the viability of the cusps. Therefore, for the present, I prefer to use living autologous tissue, and in this respect the pulmonary valve autograft has, I believe, an important and selective role to play in the younger age group, while fascia lata offers a good prospect for the future.
